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OBJECTIVES We sought to determine the use and association with one-year mortality of beta-blocker
therapy for the treatment of acute myocardial infarction (AMI) in elderly diabetic patients
and to examine whether beta-blocker therapy was associated with increased rates of hospital
readmission for diabetic complications traditionally associated with beta-blockers.
BACKGROUND Although many randomized trials have demonstrated that beta-blockers are effective in
reducing mortality after AMI, some experts are concerned about the use of beta-blockers in
diabetic patients. Little is known about the effectiveness and complication rate of beta-blocker
therapy after AMI for elderly diabetics in community practice settings.
METHODS We conducted a retrospective cohort study using the National Cooperative Cardiovascular
Project, which contained data abstracted from hospital medical records of Medicare
beneficiaries admitted with an AMI during 1994 and 1995.
RESULTS Out of 45,308 patients without contraindications to beta-blocker therapy, 7.4% were insulin-
treated diabetics and 18.5% were non-insulin-treated diabetics. Beta-blockers were prescribed at
discharge for 45% of insulin-treated diabetics, 48.1% of non-insulin-treated diabetics and 51% of
nondiabetics (p , 0.001). After adjusting for demographic and clinical factors, diabetics continued
to be less likely to receive beta-blockers at discharge compared with nondiabetics (odds ratio [OR]
for insulin-treated diabetics 0.88, 95% confidence interval [CI] 0.82 to 0.96; OR for non-insulin-
treated diabetics 0.93, 95% CI 0.88 to 0.98). After adjusting for potential confounders,
beta-blockers were associated with lower one-year mortality for insulin-treated diabetics (hazard
ratio [HR] 5 0.87, 95% CI 0.72 to 1.07), non-insulin-treated diabetics (HR 5 0.77, 95% CI 0.67
to 0.88) and nondiabetics (HR 5 0.87, 95% CI 0.80 to 0.94). Beta-blocker therapy was not
significantly associated with increased six-month readmission rates for diabetic complications
among diabetics and nondiabetics.
CONCLUSIONS Beta-blockers are associated with a lower one-year mortality rate for elderly diabetic patients
to a similar extent as for nondiabetics, without increased risk of readmission for diabetic
complications. Increasing the use of beta-blockers in elderly diabetic patients represents an
opportunity to improve the care and outcomes of these patients after AMI. (J Am Coll
Cardiol 1999;34:1388–94) © 1999 by the American College of Cardiology
Many randomized clinical trials have demonstrated the
efficacy of beta-blocker therapy in reducing mortality after
acute myocardial infarction (AMI) (1). Some experts have
raised concerns, however, about the use of beta-blockers in
patients with diabetes mellitus (2). In diabetics on insulin
therapy, beta-adrenergic blockade has been known to reduce
patient sensitivity to symptoms of hypoglycemia (3) and
delay recovery from hypoglycemia through glycogenolysis
inhibition (4,5). In type 2 diabetics, beta-blocker therapy
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has been known to exacerbate glucose intolerance (5,6) and
induce hyperosmolar hyperglycemic coma (7). The clinical
guidelines for AMI established by the American College of
Cardiology (ACC) and the American Heart Association
(AHA) (8) list insulin-dependent diabetes as a relative
contraindication to beta-blocker therapy. Hence, concerns
regarding beta-blocker use in diabetics persist even though
clinical trials have suggested that beta-blocker therapy may
reduce long-term mortality to a greater extent in diabetics
than in nondiabetics (9). Subgroup analyses from random-
ized controlled trials have found beta-blockers to be at least
as effective in diabetics as nondiabetics (10–12). However,
these trials enrolled a small number of diabetics and in-
cluded few elderly patients, a group believed to be at higher
risk for drug-associated hypoglycemia (13). The relation-
ship between use of beta-blocker therapy and outcomes for
elderly diabetics outside of clinical trials in the setting of
community practice has not been well studied.
To evaluate these issues, we conducted a study to address
the following questions: 1) Do beta-blockers improve one-
year survival for elderly diabetic patients after AMI? 2) Are
diabetic patients discharged on beta-blockers at higher risk
for hospital readmission for diabetic complications associ-
ated with therapy? To answer these questions we used data
from the Cooperative Cardiovascular Project (CCP), a
Health Care Financing Administration (HCFA) initiative
designed to examine patterns of care and improve the
outcomes of Medicare beneficiaries with AMI.
METHODS
The CCP. The CCP sample was identified from hospital
bills in the Medicare National Claims History File (form
UB-92), which included all claims submitted for patients
treated under fee-for-service plans with a principal dis-
charge diagnosis code of AMI (International Classification
of Diseases, Ninth Revision, Clinical Modification [ICD-
9-CM] 410), except those indicating a subsequent, non-
acute treatment of AMI (fifth digit of ICD-9-CM code
equal to 2) (14,15). Cooperative Cardiovascular Project
sampling was conducted for an eight-month period between
February 1994 and July 1995, except for the CCP pilot
study states (Alabama, Connecticut, Iowa and Wisconsin),
which were sampled for a four-month period between
August and November 1995. The Health Care Financing
Administration established two Clinical Data Abstraction
Centers to abstract predefined variables from copies of
hospital records, with monthly random reabstractions to
monitor data reliability.
Study sample. The study sample was restricted to patients
65 years of age or older with a confirmed AMI who were
discharged alive. A confirmed AMI was defined as a
discharge diagnosis of AMI and chart documentation of
either a creatine kinase-MB fraction .0.05, lactate dehy-
drogenase (LDH) level more than 1.5 times normal and
LDH1 . LDH2, or two of the following three criteria:
chest pain, a twofold elevation of the creatine kinase level or
a new AMI on the official electrocardiogram report.
We included only the patient’s first admission during the
sample period to avoid double-counting patients. We ex-
cluded patients who were subsequently transferred to an-
other acute care institution, because of an inability to
determine their discharge medications. We omitted three
patients in whom mortality could not be confirmed or dated.
We also excluded patients considered to have a terminal
illness (chart-documented as unlikely to live more than six
months) or metastatic cancer, because the focus of their
treatment may not have been targeted towards a survival
benefit. We replicated clinical trial criteria in order to define
a study sample of patients eligible for postdischarge beta-
blocker therapy (those without strong contraindications to
beta-blockers) based on the AMI clinical guidelines estab-
lished by the ACC/AHA in order to minimize the potential
for residual confounding (8).
Outcome variables. Mortality was ascertained from the
Medicare Enrollment Database. Hospital readmissions
were identified from Medicare Part A claims containing
data on all hospitalizations billed to Medicare. Due to the
time lag for the availability of the latest Part A data, this
study was able to consider hospital readmission only within
six months of discharge (the longest follow-up time period
available for analysis). Medicare Part A data were not
available for three of the CCP pilot states (Alabama, Iowa
and Wisconsin) and Minnesota. Overall, 95% of the pa-
tients in the study sample were included in the readmission
analysis. We examined hospital readmissions for acute
diabetic conditions (uncomplicated diabetes, ketoacidosis,
hyperosmolarity, diabetic coma, hypoglycemia [ICD-9
codes 250.0 to 250.4, 250.8 to 250.9]) and readmissions for
diabetes with renal, ophthalmic, neurological or peripheral
vascular complications (ICD-9 codes 250.4 to 250.7).
Independent variables. The principal independent vari-
ables of interest were prescription of beta-blockers at dis-
charge and history of diabetes. We identified all patients
with an oral beta-blocker as a discharge medication. We
classified patients as insulin-treated diabetics (patients pre-
scribed insulin at discharge), non-insulin-treated diabetics
and nondiabetics based on chart review. Although we were
unable to distinguish between type I and type II diabetes, we
Abbreviations and acronyms
ACC 5 American College of Cardiology
AHA 5 American Heart Association
AMI 5 acute myocardial infarction
CCP 5 Cooperative Cardiovascular Project
HCFA 5 Health Care Financing Administration
LDH 5 lactate dehydrogenase
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expect the majority of diabetics to have type II disease, given
the advanced age of the cohort.
Because differences in baseline characteristics between
diabetics and nondiabetics may bias the association between
beta-blockers and survival or readmission, we selected a set
of variables to control for potential confounding. These
variables were selected on the basis of previous work,
strength of association and clinical relevance, and they
included the characteristics listed in Table 2 along with the
region of the hospitalization as defined by the U.S. Census
(16). Hospital length of stay was coded as greater than 12
days (yes/no), the 85th percentile for length of stay. We
classified the attending physician’s specialty by linking the
Unique Physician Identification Number listed in Medicare
Part A claims with a directory of physician-reported spe-
cialties maintained by the HCFA, as in a previous report
(17). For variables with more than 3% missing values (i.e.,
prothrombin time and albumin), a dummy variable was
created and included in the multivariate analyses.
Statistical analysis. We first compared the use of beta-
blocker therapy and differences in baseline characteristics
among insulin-treated diabetics, non-insulin-treated dia-
betics and nondiabetics. The chi-square test was used for
categorical variables, and analysis of variance was used for
continuous variables. We used bivariate and multivariate
logistic regression analyses to determine if diabetics were
less likely to receive beta-blocker therapy at discharge than
nondiabetics. The analysis was repeated among patients
who were not on beta-blocker therapy before admission for
the AMI.
In the second part of the analysis, we estimated the
association between the prescribed use of beta-blockers at
discharge and one-year survival in an unadjusted model and
after adjusting for potential confounders with a Cox pro-
portional hazards model. The assumption of proportionality
was evaluated graphically and found to be satisfactory. We
then evaluated whether the association between beta-
blockers and one-year mortality differed among diabetics
and nondiabetics in a combined interaction model.
Finally, we evaluated whether beta-blocker therapy was
associated with increased rates of hospital admission for
diabetic complications. We used log-linear Poisson regres-
sion models to estimate the hospital readmission rate,
adjusting for prescribed beta-blocker use and other potential
confounders. Among patients who were treated and not
treated with beta-blockers, we examined the rates of read-
mission for all diabetic complications as well as readmissions
for acute diabetic events only.
RESULTS
Study sample. Of the 115,015 eligible patients (65 years of
age or older, confirmed AMI, survived the hospitalization,
no terminal illness and not transferred), 69,707 patients
(61%) had one or more strong contraindications to beta-
blocker therapy (Table 1). Our final study sample included
45,308 elderly AMI patients with no relative contraindica-
tions to beta-blocker therapy other than diabetes.
Of the 45,308 patients in the study sample, 3,347 (7.4%)
were diabetics who were prescribed insulin at discharge,
8,370 (18.5%) were diabetics who were not prescribed
insulin at discharge and 33,591 (74.1%) were nondiabetics.
Insulin and non-insulin-treated diabetics were younger on
average than nondiabetics. As expected, diabetics had
higher rates of hypertension, prior AMI, congestive heart
failure, peripheral vascular disease and renal dysfunction
compared with nondiabetics (Table 2).
Comparison of patients receiving and not receiving
beta-blockers. Of the 45,308 patients eligible for beta-
blocker therapy, 22,665 (50%) had a beta-blocker prescribed
as a discharge medication. Characteristics associated with
patients receiving a prescription for beta-blockers at dis-
charge have been described in a previous article (18).
Younger age, white race, hypertension and higher left
ventricular ejection fraction were characteristics associated
with higher receipt of beta-blockers. Of note, patients
prescribed calcium channel blockers at discharge were less
likely to receive beta-blocker therapy.
Prescribed use of beta-blockers by diabetes status. There
were significant differences in the prescribed use of beta-
blocker therapy by diabetes status: 45% of insulin-treated
Table 1. Definition of the Study Sample
No. of
Subjects
Total sample 234,769
Exclusions*
Age ,65 yrs 17,593
AMI not confirmed 31,186
Total patients $65 yrs with confirmed AMI 188,309
Transfer out 32,995
In-hospital death 26,856
Death undetermined 3
Repeat admissions 13,893
Terminal illness, metastatic cancer 3,860
Total baseline 115,015
Contraindications
Last recorded heart rate ,50 beats/min at
discharge
1,266
Last recorded SBP ,100 mm Hg at
discharge
6,502
Heart failure during the hospitalization 54,005
2° or 3° atrioventricular block 4,389
Asthma/COPD 23,778
Allergy or intolerance to beta-blockers 1,115
At least one of the above 69,707
Study sample of patients eligible for beta-blocker
therapy
45,308
*Categories are not mutually exclusive.
AMI 5 acute myocardial infarction; COPD 5 chronic obstructive pulmonary
disease; SBP 5 systolic blood pressure.
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diabetics, 48.2% of non-insulin-treated diabetics and 51% of
nondiabetics received beta-blockers (p , 0.001). However,
these differences were mediated, in part, by differences in
clinical characteristics between the three groups. After
adjusting for demographic and clinical factors, both non-
insulin-treated diabetics and insulin-treated diabetics con-
tinued to be less likely to be prescribed beta-blocker therapy
(odds ratio [OR] 0.88, 95% confidence interval [CI] 0.82 to
0.96; and OR 0.93, 95% CI 0.88 to 0.98, respectively) than
nondiabetics. Of the 36,794 patients not on beta-blocker
therapy before admission, 16,006 (43.5%) were prescribed
therapy at discharge. There were also significant differences
in the initiation of beta-blocker therapy by diabetes status:
beta-blockers were prescribed for 37.0% of the insulin-
treated diabetics, 41.1% of the non-insulin-treated diabetics
and 44.8% of the nondiabetics (p , 0.001). In the adjusted
analysis, both non-insulin-treated diabetics and insulin-
treated diabetics were less likely to receive beta-blockers at
discharge (OR 0.95, 95% CI 0.89 to 1.01; and OR 0.90,
95% CI 0.82 to 0.99, respectively) than nondiabetics.
Association with survival. Overall, patients prescribed
beta-blocker therapy at discharge had a one-year mortality
rate of 7.7% compared with 12.6% for patients who were
not prescribed the therapy (p , 0.001). Beta-blockers were
associated with increased survival among insulin-treated
diabetics (12.5% vs. 17.8%, p , 0.001), non-insulin-treated
diabetics (8.9% vs. 15.2%, p , 0.001) and nondiabetics (7%
vs. 11.3%, p , 0.001). The differences in survival observed
were due in part to the higher severity of illness in diabetic
patients.
In analyses that adjusted for demographic and clinical
confounders, the prescribed use of beta-blockers was asso-
ciated with lower risk of mortality for non-insulin-treated
diabetics (hazard ratio [HR] 5 0.77, 95% CI 0.67 to 0.89)
and nondiabetics (HR 5 0.88, 95% CI 0.81 to 0.95). While
not statistically significant, the estimate of the effectiveness
of beta-blocker therapy for insulin-treated diabetics was
identical to that for nondiabetics (HR 5 0.89, 95% CI 0.73
to 1.08). A combined regression model that included
diabetics and nondiabetics found no significant interactions
between beta-blocker effectiveness and type of diabetes.
Association with readmission. The six-month readmis-
sion rates for diabetic complications were similar both for
patients who were and who were not prescribed beta-
blockers among insulin-treated diabetics (2.3% vs. 3.5%,
p 5 0.06), non-insulin-treated diabetics (0.8% vs. 1.3%,
p 5 0.07) and nondiabetics (0.04% vs. 0.06%, p 5 0.60).
There was no significant increase in the risk of readmission
for diabetic complications for patients prescribed beta-
blockers in adjusted analyses (risk ratio [RR] 5 0.72, 95%
CI 0.44 to 1.19 for insulin-treated diabetics; RR 5 0.81,
95% CI 0.51 to 1.28 for non-insulin-treated diabetics; and
RR 5 0.80, 95% CI 0.27 to 2.34 for nondiabetics).
The rate of readmission for acute diabetic events alone
(hypoglycemia, hyperglycemia or diabetic coma) was not
higher for patients on beta-blocker therapy versus those who
were not among insulin-treated diabetics (1.2% vs. 2.3%, p
5 0.02), non-insulin-treated diabetics (0.5% vs. 0.7%, p 5
0.27) and nondiabetics (0.04% vs. 0.05%, p 5 0.99).
Beta-blockers were not associated with increased risk for
readmission for acute diabetic events among insulin-treated
diabetics (RR 5 0.52, 95% CI 0.27 to 1.00), non–insulin-
treated diabetics (RR 5 0.82, 95% CI 0.43 to 1.56), and
nondiabetics (RR 5 1.14, 95% CI 0.35 to 3.70). In models
that combined diabetics and nondiabetics, we did not find
significant interactions between diabetes and beta-blockers
for readmission for diabetic complications.
DISCUSSION
The prescribed use of beta-blockers was significantly asso-
ciated with lower one-year mortality among non-insulin-
treated diabetics, and although not statistically significant,
beta-blocker therapy was found to have similar effectiveness
for insulin-treated diabetics and nondiabetics. Neither
insulin-treated nor non-insulin-treated diabetics were at
increased risk of readmission for diabetic complications;
both groups, however, were significantly less likely to be
prescribed beta-blocker therapy compared with nondiabet-
ics.
There are at least two explanations why the relationship
between beta-blockers and lower mortality was not statisti-
cally significant for insulin-treated diabetics. One possibility
is that our population was too small to demonstrate a
survival benefit in this group. However, the fact that the
effect sizes of beta-blocker therapy in insulin-treated dia-
betics and nondiabetics were similar suggests that treatment
was beneficial. The lack of interaction between beta-
blockers and insulin use also suggests that beta-blocker
therapy is effective for insulin-treated diabetics.
Alternatively, it is conceivable that the benefit from
beta-blocker therapy is smaller for insulin-treated diabetics.
Beta-blockers and insulin have similar effects on metabolic
mechanisms that may be protective after AMI, such as
reducing serum levels of fatty acids. During times of
ischemia, fatty acids and their metabolites have been impli-
cated in aggravating myocardial injury due to their chemical
toxicity and increased oxygen demand (19). Both beta-
blockers (20) and insulin-glucose infusions (21) have been
shown to decrease plasma-free fatty acid levels. Thus, it is
possible that decreased benefit of beta-blockers observed in
the insulin-treated diabetics of our study may be due to
some degree of overlap of beneficial mechanisms. This
would be consistent with the findings from the DIGAMI
study, where in multivariate analysis, insulin appeared to be
less effective in diabetic patients on beta-blocker therapy
after AMI (22).
Previous studies. The finding that most diabetics appear
to benefit from beta-blocker therapy after AMI is consistent
with results from subgroup analyses of randomized con-
trolled trials focusing on diabetic patients (10–12). All of
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Table 2. Bivariate Analysis of Characteristics Associated With Diabetic and Nondiabetic Patients in Study Sample
Percent of
Nondiabetics
With
Characteristic
Percent of
Non-insulin-receiving
Diabetics With
Characteristic
Percent of
Insulin-receiving
Diabetics With
Characteristic
p
Value
All eligible patients n 5 33,591 n 5 8,370 n 5 3,347
Demographics
Age 65–74 yrs 50.4% 52.6% 58.1% , 0.001
Age 75–84 yrs 36.5% 37.9% 35.9% 0.041
Age $85 yrs 13.1% 9.6% 6.0% , 0.001
White race 91.5% 85.5% 83.1% , 0.001
Black race 5.3% 8.3% 11.4% , 0.001
Other race 3.2% 5.8% 5.5% , 0.001
Female gender 44.2% 47.2% 56.0% , 0.001
Past medical history and comorbidity
Hypertension 57.3% 71.7% 71.4% , 0.001
Current smoker 13.3% 9.8% 6.8% , 0.001
Myocardial infarction 23.5% 28.0% 31.7% , 0.001
Congestive heart failure 5.5% 8.8% 12.6% , 0.001
CABG 12.6% 14.0% 16.8% , 0.001
PTCA 7.7% 9.1% 10.7% , 0.001
Peripheral vascular disease 5.8% 10.1% 15.9% , 0.001
Stroke 10.1% 14.6% 17.8% , 0.001
Dementia 4.7% 4.6% 5.0% 0.659
Inability to ambulate 14.0% 18.0% 24.2% , 0.001
Admission characteristics
Chest pain 27.1% 29.4% 29.0% , 0.001
Stroke on admission 0.7% 0.7% 1.1% 0.015
Left bundle branch block 3.3% 3.5% 4.2% 0.012
Ventricular tachycardia 0.3% 0.4% 0.5% 0.242
Respiration .25/min 5.9% 6.1% 8.0% , 0.001
BUN .40 mg/dl or Creatine .2.5 mg/dl 3.6% 5.7% 9.6% , 0.001
Hematocrit ,30% 2.9% 2.8% 3.4% 0.264
Prothrombin time .16 s 4.9% 4.5% 4.7% 0.367
Albumin ,3 mg/dl 2.7% 2.6% 4.4% , 0.001
Location of infarction
Anterior 40.8% 41.4% 40.3% 0.504
Inferior 50.1% 50.0% 47.1% 0.004
Left ventricular systolic function
LVEF 0%–19% 0.4% 0.5% 0.8% , 0.001
LVEF 20%–39% 11.2% 13.2% 12.3% , 0.001
LVEF 40%–54% 39.2% 37.6% 35.9% , 0.001
LVEF $55% 20.3% 18.8% 17.9% , 0.001
Ejection fraction undetermined 29.0% 29.8% 33.2% , 0.001
Hospital treatments, procedures and course
Thrombolytic therapy 17.2% 14.7% 13.1% , 0.001
PTCA 24.0% 20.5% 17.5% , 0.001
CABG 10.7% 11.0% 10.0% 0.257
Peak CK
,2 times normal 36.3% 40.1% 40.8% , 0.001
2–4 times normal 24.9% 25.1% 26.0% 0.425
4–10 times normal 24.7% 22.5% 21.4% , 0.001
.10 times normal 10.2% 8.5% 8.2% , 0.001
Length of stay .12 days 12.9% 15.0% 16.4% , 0.001
Discharge medications
Aspirin 75.3% 71.6% 74.0% , 0.001
ACE inhibitors 21.1% 27.2% 32.5% , 0.001
Beta-blockers 51.0% 48.2% 45.0% , 0.001
Calcium channel blockers 36.2% 40.9% 46.9% , 0.001
Loop diuretics 14.8% 21.0% 29.8% , 0.001
(continued on next page)
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these studies demonstrated that beta-blocker therapy was
associated with greater relative reduction in mortality for
diabetics compared with nondiabetics, although their co-
horts were younger on average than those in the CCP. In
the Beta-Blocker Heart Attack Trial (BHAT), where 55
out of 4,163 patients had diabetes, there was a 35%
reduction in 25-month mortality among diabetic patients
and a 25% reduction among nondiabetic patients (10). In
the Norwegian Multicenter Timolol Study, 99 of 1,884
patients had diabetes. In a mean follow-up period of 17
months, timolol treatment was associated with reduction in
cardiac mortality of 63% in diabetic patients and 34% in
nondiabetic patients (11). In the Go¨teborg Metoprolol
Trial, in which 120 of 1,395 patients were diabetic, the
reduction of three-month mortality was greater in diabetics
(58%) than nondiabetics (30%) (12).
Our findings are also consistent with other non-
randomized cohort studies that suggest beta-blockers are ef-
fective in reducing long-term mortality from AMI (10,23).
Clinical studies have found beta-blockers to be generally
safe in diabetic patients. In a prospective study of 150
insulin-treated diabetics, the incidence of loss of conscious-
ness as a result of hypoglycemia was the same for those
subjects receiving and not receiving beta-blocker therapy,
approximately 1 out of 50 patients taking beta-blockers
(24). Beta-blockers have also been found to be a safe
treatment for hypertension in older diabetic patients. A
recent study from the United Kingdom Diabetes Study
Group found that beta-blockers reduced the risk of micro-
vascular and macrovascular complications in type 2 diabet-
ics, without an increased risk for hypoglycemic events or
worsened serum lipid profiles (25). In another study of over
13,000 elderly diabetics who were concurrently using insulin
or sulfonylureas, beta-blocker therapy was not significantly
associated with higher rates of serious hypoglycemia requir-
ing hospitalization (26).
Our findings are consistent with those of a study using
the CCP data set that examined the use of beta-blockers in
patients with relative contraindications (27); however, the
estimates of the effectiveness of beta-blockers differ. The
risk reduction associated with beta-blockers for diabetics in
the study by Gottlieb et al. (27) was 36% (95% CI 31% to
40%), greater than that found for this study. However, the
study by Gottlieb et al. (27) included patients with relative
contraindications to beta-blockers (such as heart failure and
chronic obstructive pulmonary disease) without adjustment
for the severity of these conditions. For example, diabetic
patients who received beta-blockers were less likely to suffer
from severe heart failure. Because patients with severe heart
failure were both less likely to receive beta-blockers and
more likely to die than patients with less severe disease, the
outcomes may be biased towards the finding that beta-
blockers have benefit. In contrast, this study restricted the
analysis to patients without contraindications to therapy,
reducing subsequent confounding and obtaining estimates
of beta-blocker benefit similar to those reported in the
clinical trials (1).
Study limitations. This study has several limitations. First,
findings from retrospective studies are subject to limitations
due to their nonexperimental design. Although our analysis
controlled for a wide range of demographic, clinical, labo-
ratory and functional characteristics, we cannot exclude the
possibility that the benefit associated with beta-blocker
therapy was a result of residual confounding. Because our
ability to identify contraindications to beta-blocker therapy
and adjust for confounding risk factors was limited by the
information documented in the medical charts, there may
have been unknown factors associated with improved sur-
vival that were also associated with the use of beta-blockers.
Second, although the use of beta-blockers was based on
retrospective chart review, we do not have information
regarding long-term compliance with therapy in the year
after discharge and may have misclassified the long-term
Table 2. Continued
Percent of
Nondiabetics
With
Characteristic
Percent of
Non-insulin-receiving
Diabetics With
Characteristic
Percent of
Insulin-receiving
Diabetics With
Characteristic
p
Value
Discharge disposition
Home 90.4% 90.3% 88.6% 0.002
Skilled nursing facility 6.3% 6.4% 8.0% , 0.001
Other 3.3% 3.3% 3.5% 0.843
Physician specialty
Cardiology 42.0% 37.5% 34.4% , 0.001
Internal medicine 37.7% 39.8% 41.9% , 0.001
Family/general medicine 17.2% 18.1% 18.4% 0.042
Other/missing 12.4% 13.2% 13.5% 0.033
Excludes missing values for heart rate, respiratory rate, systolic blood pressure, hematocrit, prothrombin time, BUN, creatinine, albumin and creatine kinase. p Values obtained
using the chi-square test.
ACE 5 angiotensin-converting enzyme; BUN 5 blood urea nitrogen; CABG 5 coronary artery bypass grafting surgery; LVEF 5 left ventricular ejection fraction;
PTCA 5 percutaneous transluminal coronary angioplasty.
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patterns of use in some patients. However, this misclassifi-
cation would bias the relationship between the use of
beta-blockers and improved survival towards the null.
Third, our ability to determine whether patients were
diabetic was based on documentation in the medical charts
rather than from serum glucose or hemoglobin A1c values.
We were able to indirectly confirm the validity of diabetes
status from medication use, and in analyses where diabetes
status was defined by use of hypoglycemic agents or insulin,
our results were similar to analyses wherein diabetes status
was based on chart-documentation. Fourth, while beta-
blockers were not associated with higher risk for readmis-
sion, our study was unable to assess whether therapy was
associated with episodes of hypoglycemia or worsening
diabetic control that did not lead to hospitalization. Lastly,
we cannot exclude the possibility that the diabetic patients
who were able to tolerate beta-blockers were the ones who
received therapy, thus selecting diabetics who would benefit
the most from treatment.
Conclusions. The findings from this study, combined with
those from clinical trials, suggest that beta-blockers are at
least as effective for diabetics as for nondiabetics at no
increased risk for diabetic complications. Even if the relative
reduction in mortality from beta-blocker therapy were the
same for diabetics and nondiabetics, beta-blockers would
still have the potential to save more lives because the
baseline mortality is higher in diabetics than nondiabetics
(28). The results from this study may serve to alleviate
physicians’ concerns about prescribing beta-blockers to di-
abetic patients after AMI and help ensure that more of these
high-risk patients have the opportunity to benefit from their
use.
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